UBS analyst Dan Leonard raised the firm’s price target on 10x Genomics (TXG) to $13 from $12 and keeps a Neutral rating on the shares. While 10x Genomics reported a quarterly beat, the muted environment is here to stay, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $14 from $10 at Deutsche Bank
- 10x Genomics: Balanced Outlook Amid Growth and Uncertainties
- 10x Genomics price target raised to $15 from $13 at Barclays
- 10x Genomics Reports Strong Q2 2025 Results
- 10x Genomics: Hold Rating Amidst Macroeconomic Challenges and Strategic Moves